Sanofi presents insulin findings at International Diabetes Foundation congress

4 December 2019
syringe_syringes_big

French drugmaker Sanofi (Euronext: SAN) is presenting clinical data from its insulin portfolio at the 2019 congress of the International Diabetes Federation (IDF), in Busan, South Korea.

The firm is offering details from a new comparison of gastrointestinal adverse events with a GLP-1 receptor agonist and Soliqua (insulin glargine/lixisenatide), a combination therapy containing both a long-acting human insulin analog and a GLP-1 receptor agonist.

In a separate presentation, a post-hoc sub-analysis of the BRIGHT study of Toujeo (insulin glargine) will also be unveiled, showing outcomes for Toujeo versus insulin degludec in older adults with type 2 diabetes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology